Local anesthetic-like inhibition of voltage-gated Na + channels by the partial μ-opioid receptor agonist buprenorphine

Anesthesiology

Volumn 116, Issue 6, 2012, Pages 1335-1346

  Leffler, Andreas ^a   Frank, Georg ^b   Kistner, Katrin ^b   Niedermirtl, Florian ^b   Koppert, Wolfgang ^a   Reeh, Peter W ^b   Nau, Carla ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL; MORPHINE; REMIFENTANIL; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; SUFENTANIL; TRAMADOL;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LOCAL ANESTHESIA; NERVE ENDING; NERVE POTENTIAL; NONMYELINATED NERVE; PATCH CLAMP; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SKIN NERVE; SODIUM CURRENT; WHOLE CELL;

ACTION POTENTIALS; ANESTHETICS, LOCAL; ANIMALS; BUPRENORPHINE; CELL LINE; DATA INTERPRETATION, STATISTICAL; GANGLIA, SPINAL; HUMANS; LIDOCAINE; MICE; MICE, INBRED C57BL; NARCOTICS; NERVE FIBERS; NERVE FIBERS, UNMYELINATED; PATCH-CLAMP TECHNIQUES; RECEPTORS, OPIOID, MU; SKIN; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TETRODOTOXIN;

EID: 84861596787     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182557917     Document Type: Article

References (47)

1. Li X, Keith DE Jr, Evans CJ: Multiple opioid receptor-like genes are identified in diverse vertebrate phyla. FEBS Lett 1996; 397:25-9
2. Kieffer BL: Opioid receptors: From genes to mice. J Pain 2000; 1:45-50
3. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL: Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383:819-23
4. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR: Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94:1544-9
5. Kieffer BL: Opioids: First lessons from knockout mice. Trends Pharmacol Sci 1999; 20:19-26
6. Gavériaux-Ruff C, Kieffer BL: Opioid receptor genes inactivated in mice: The highlights. Neuropeptides 2002; 36: 62-71
7. Grudt TJ, Williams JT:μ-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat. J Neurosci 1994; 14:1646-54
8. Kohno T, Kumamoto E, Higashi H, Shimoji K, Yoshimura M: Actions of opioids on excitatory and inhibitory transmission in substantia gelatinosa of adult rat spinal cord. J Physiol 1999; 518(Pt 3):803-13
9. Koppert W, Schmelz M: The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol 2007; 21:65-83
10. Simonnet G, Rivat C: Opioid-induced hyperalgesia: Abnormal or normal pain? Neuroreport 2003; 14:1-7
11. Koppert W, Ihmsen H, Körber N, Wehrfritz A, Sittl R, Schmelz M, Schüttler J: Different profiles of buprenorphineinduced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118:15-22
12. Lutfy K, Cowan A: Buprenorphine: A unique drug with complex pharmacology. Curr Neuropharmacol 2004; 2:395-402
13. Kress HG: Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13: 219-30
14. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ: Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003; 23:10331-7
15. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang ET, Malan TP Jr, Ossipov MH, Lai J, Porreca F: Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074-9
16. Dickenson AH, Sullivan AF, McQuay HJ: Intrathecal etorphine, fentanyl and buprenorphine on spinal nociceptive neurones in the rat. Pain 1990; 42:227-34
17. Varrassi G, Marinangeli F, Ciccozzi A, Iovinelli G, Facchetti G, Ciccone A: Intra-articular buprenorphine after knee arthroscopy. A randomised, prospective, double-blind study. Acta Anaesthesiol Scand 1999; 43:51-5
18. Kolesnikov YA, Chereshnev I, Pasternak GW: Analgesic synergy between topical lidocaine and topical opioids. J Pharmacol Exp Ther 2000; 295:546-51
19. Koppert W, Dern SK, Sittl R, Albrecht S, Schüttler J, Schmelz M: A new model of electrically evoked pain and hyperalgesia in human skin: The effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. ANESTHESIOLOGY 2001; 95:395-402
20. Nau C, Wang GK: Interactions of local anesthetics with voltage-gated Na+channels. J Membr Biol 2004; 201:1-8
21. Leffler A, Reckzeh J, Nau C: Block of sensory neuronal Na+channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol 2010; 630:19-28
22. Leffler A, Reiprich A, Mohapatra DP, Nau C: Use-dependent block by lidocaine but not amitriptyline is more pronounced in tetrodotoxin (TTX)-Resistant Nav1.8 than in TTX-sensitive Na+channels. J Pharmacol Exp Ther 2007; 320:354-64
23. Reeh PW: Sensory receptors in mammalian skin in an in vitro preparation. Neurosci Lett 1986; 66:141-6
24. Zimmermann K, Hein A, Hager U, Kaczmarek JS, Turnquist BP, Clapham DE, Reeh PW: Phenotyping sensory nerve endings in vitro in the mouse. Nat Protoc 2009; 4:174-96
25. Nau C, Wang SY, Wang GK: Point mutations at L1280 in Nav1.4 channel D3-S6 modulate binding affinity and stereoselectivity of bupivacaine enantiomers. Mol Pharmacol 2003; 63:1398-406
26. Nau C, Wang SY, Strichartz GR, Wang GK: Point mutations at N434 in D1-S6 of mu1 Na(+) channels modulate binding affinity and stereoselectivity of local anesthetic enantiomers. Mol Pharmacol 1999; 56:404-13
27. Sheets MF, Fozzard HA, Lipkind GM, Hanck DA: Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med 2010; 20:16-21
28. Hanck DA, Nikitina E, McNulty MM, Fozzard HA, Lipkind GM, Sheets MF: Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res 2009; 105:492-9
29. Wang GK, Russell C, Wang SY: Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+channels. J Physiol 2004; 554:621-33
30. Wang GK, Russell C, Wang SY: State-dependent block of wild-type and inactivation-deficient Na+channels by flecainide. J Gen Physiol 2003; 122:365-74
31. Lampert A, O'Reilly AO, Reeh P, Leffler A: Sodium channelopathies and pain. Pflugers Arch 2010; 460:249-63
32. Haeseler G, Foadi N, Ahrens J, Dengler R, Hecker H, Leuwer M: Tramadol, fentanyl and sufentanil but not morphine block voltage-operated sodium channels. Pain 2006; 126:234-44
33. Wagner LE 2nd, Eaton M, Sabnis SS, Gingrich KJ: Meperidine and lidocaine block of recombinant voltage-dependent Na+channels: Evidence that meperidine is a local anesthetic. ANESTHESIOLOGY 1999; 91:1481-90
34. Su X, Joshi SK, Kardos S, Gebhart GF: Sodium channel blocking actions of the kappa-opioid receptor agonist U50, 488 contribute to its visceral antinociceptive effects. J Neurophysiol 2002; 87:1271-9
35. Yanagidate F, Strichartz GR: Local anesthetics. Handb Exp Pharmacol 2007:95-127
36. Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35:501-16
37. Kistner K, Zimmermann K, Ehnert C, Reeh PW, Leffler A: The tetrodotoxin-resistant Na+channel Na (v)1.8 reduces the potency of local anesthetics in blocking C-fiber nociceptors. Pflugers Arch 2010; 459:751-63
38. Brodin P, Skoglund LA: Dose-response inhibition of rat compound nerve action potential by dextropropoxyphene and codeine compared to morphine and cocaine in vitro. Gen Pharmacol 1990; 21:551-3
39. Mizuta K, Fujita T, Nakatsuka T, Kumamoto E: Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures. Life Sci 2008; 83:198-207
40. Likar R, Sittl R: Transdermal buprenorphine for treating nociceptive and neuropathic pain: Four case studies. Anesth Analg 2005; 100:781-5
41. Benedetti F, Vighetti S, Amanzio M, Casadio C, Oliaro A, Bergamasco B, Maggi G: Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998; 74:205-11
42. Filitz J, Ihmsen H, Günther W, Tröster A, Schwilden H, Schüttler J, Koppert W: Supra-additive effects of tramadol and acetaminophen in a human pain model. Pain 2008; 136:262-70
43. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M: Shortterm infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106:49-57
44. Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M: Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain 2000; 85:217-24
45. Koppert W, Zeck S, Sittl R, Likar R, Knoll R, Schmelz M: Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans. ANESTHESIOLOGY 1998; 89:1345-53
46. Wang SY, Mitchell J, Moczydlowski E, Wang GK: Block of inactivation-deficient Na+channels by local anesthetics in stably transfected mammalian cells: Evidence for drug binding along the activation pathway. J Gen Physiol 2004; 124: 691-701
47. Axelsson K, Gupta A: Local anaesthetic adjuvants: Neuraxial versus peripheral nerve block. Curr Opin Anaesthesiol 2009; 22:649-54